Abstract
Pulmonary fibrosis is an unremitting degenerative lung disease that has an associated high mortality. The major pathological features include the growth of fibroblasts, emergence of myofibroblasts and their production of extracellular matrix that distorts the peripheral lung tissue and impairs respiratory function. Efforts to pharmacologically reduce inflammation, inhibit fibroblast growth, or matrix synthesis have not been successful in ameliorating disease. Genetic mutations associated with rare hereditary forms of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) link definitive causes to this enigmatic group of diseases. The generation of mouse models with similar genetic lesions or deficiencies is providing insight into the mechanisms that lead to fibrosis. Mutations that alter components of pulmonary surfactant or surfactant homeostasis have been associated with specific forms of ILD and/or IPF. This small but growing collection of IPF related surfactant dysfunction mutations implicate respiratory epithelial cell injury as an early event in the molecular pathogenesis and progression of fibrosis. Determining the mechanisms for genetically defined examples of IPF should be informative for investigating the larger segment of IPF where the underlying cause remains obscure.
Keywords: Transgenic mice, Gene targeted mice, ILD-Interstitial Lung Disease, IPF-Idiopathic Pulmonary Fibrosis, myofibroblasts, inhibit fibroblast growth, idiopathic pulmonary fibrosis (IPF), genetic lesions, surfactant homeostasis, epithelial cell, molecular pathogenesis, infectious agents, Less pronounced fibrosis, fibrotic elements, epithelial cell defect
Current Pharmaceutical Biotechnology
Title: Use of Transgenic Mouse Models to Understand the Origins of Familial Pulmonary Fibrosis
Volume: 12 Issue: 9
Author(s): Stephan W. Glasser and Albert P. Senft
Affiliation:
Keywords: Transgenic mice, Gene targeted mice, ILD-Interstitial Lung Disease, IPF-Idiopathic Pulmonary Fibrosis, myofibroblasts, inhibit fibroblast growth, idiopathic pulmonary fibrosis (IPF), genetic lesions, surfactant homeostasis, epithelial cell, molecular pathogenesis, infectious agents, Less pronounced fibrosis, fibrotic elements, epithelial cell defect
Abstract: Pulmonary fibrosis is an unremitting degenerative lung disease that has an associated high mortality. The major pathological features include the growth of fibroblasts, emergence of myofibroblasts and their production of extracellular matrix that distorts the peripheral lung tissue and impairs respiratory function. Efforts to pharmacologically reduce inflammation, inhibit fibroblast growth, or matrix synthesis have not been successful in ameliorating disease. Genetic mutations associated with rare hereditary forms of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) link definitive causes to this enigmatic group of diseases. The generation of mouse models with similar genetic lesions or deficiencies is providing insight into the mechanisms that lead to fibrosis. Mutations that alter components of pulmonary surfactant or surfactant homeostasis have been associated with specific forms of ILD and/or IPF. This small but growing collection of IPF related surfactant dysfunction mutations implicate respiratory epithelial cell injury as an early event in the molecular pathogenesis and progression of fibrosis. Determining the mechanisms for genetically defined examples of IPF should be informative for investigating the larger segment of IPF where the underlying cause remains obscure.
Export Options
About this article
Cite this article as:
W. Glasser Stephan and P. Senft Albert, Use of Transgenic Mouse Models to Understand the Origins of Familial Pulmonary Fibrosis, Current Pharmaceutical Biotechnology 2011; 12 (9) . https://dx.doi.org/10.2174/138920111798281045
DOI https://dx.doi.org/10.2174/138920111798281045 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews Characterization of Cepharanthin Nanosuspensions and Evaluation of Their In Vitro Activity for the HepG2 Hepatocellular Carcinoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) In vivo Distribution of Tiotropium in a Rodent Model Utilizing AP-SMALDI Mass Spectrometry Imaging
Current Analytical Chemistry Emerging Therapies in the Treatment of Locally Advanced Squamous Cell Cancers of Head and Neck
Recent Patents on Anti-Cancer Drug Discovery Role of Phase II Drug Metabolizing Enzymes in Cancer Chemoprevention
Current Drug Metabolism Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
Current Medicinal Chemistry Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Retinoids in Clinical Use
Medicinal Chemistry Colloidal Drug Delivery Systems in Vaccine Delivery
Current Drug Targets Chemical Advances in Therapeutic Application of Exosomes and Liposomes
Current Medicinal Chemistry The Role of PEDF in Tumor Growth and Metastasis
Current Molecular Medicine Mitocans: Mitochondrial Targeted Anti-Cancer Drugs as Improved Therapies and Related Patent Documents
Recent Patents on Anti-Cancer Drug Discovery Pulmonary Drug Delivery: A Role for Polymeric Nanoparticles?
Current Topics in Medicinal Chemistry Potential Molecular Targets of Ampelopsin in Prevention and Treatment of Cancers
Anti-Cancer Agents in Medicinal Chemistry Copper Compounds in Cancer Chemotherapy
Current Medicinal Chemistry The Role of microRNAs in the Diagnosis and Treatment of Malignant Pleural Mesothelioma - A Short Review
MicroRNA Secondary Metabolites from Cyanobacteria: Complex Structures and Powerful Bioactivities
Current Organic Chemistry